This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1xdd

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1xdd.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1xdd.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1xdd| PDB=1xdd | SCENE= }}
{{STRUCTURE_1xdd| PDB=1xdd | SCENE= }}
-
'''X-ray structure of LFA-1 I-domain in complex with LFA703 at 2.2A resolution'''
+
===X-ray structure of LFA-1 I-domain in complex with LFA703 at 2.2A resolution===
-
==Overview==
+
<!--
-
The integrin lymphocyte function-associated antigen-1 (LFA-1) (alphaLbeta2; CD11a/CD18) plays an important role in leukocyte migration and T cell activation. LFA-1 is inhibited by the cholesterol-lowering drug lovastatin, which binds to an allosteric site of the alphaL I domain termed the lovastatin site (L-site). Here we report for the first time the x-ray structures of the LFA-1 I domain complexed with derivatives of lovastatin optimized for LFA-1 inhibition. This analysis identified two new subpockets within the L-site occupied by chemical groups of the statin derivatives but not by lovastatin itself. Occupancy of these L-site subpockets led to distinct conformational changes in LFA-1, which were detectable by an epitope-monitoring assay. We utilized this assay to demonstrate improved LFA-1 inhibition in human blood in vitro and in blood samples from treated animals ex vivo. Moreover, we demonstrate that the novel lovastatin-derived LFA-1 inhibitor LFA878 exhibits potent anti-inflammatory effects in carrageenan-induced rat paw edema. In summary, the findings reported here extend the understanding of LFA-1 inhibition at the molecular level, allow for the identification and design of LFA-1 inhibitors of further enhanced potency, and support the expectation that LFA-1 inhibitors binding to the L-site will be of therapeutic value in treating inflammatory diseases.
+
The line below this paragraph, {{ABSTRACT_PUBMED_15304496}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 15304496 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_15304496}}
==About this Structure==
==About this Structure==
Line 28: Line 32:
[[Category: I-domain]]
[[Category: I-domain]]
[[Category: Rossman fold]]
[[Category: Rossman fold]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 14:53:12 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Jul 27 13:27:16 2008''

Revision as of 10:27, 27 July 2008

Image:1xdd.png

Template:STRUCTURE 1xdd

X-ray structure of LFA-1 I-domain in complex with LFA703 at 2.2A resolution

Template:ABSTRACT PUBMED 15304496

About this Structure

1XDD is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives: molecular basis determined by x-ray analysis and monitoring of LFA-1 conformational changes in vitro and ex vivo., Weitz-Schmidt G, Welzenbach K, Dawson J, Kallen J, J Biol Chem. 2004 Nov 5;279(45):46764-71. Epub 2004 Aug 10. PMID:15304496

Page seeded by OCA on Sun Jul 27 13:27:16 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1xdd"
Personal tools